Literature DB >> 25447766

Interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in minimal hepatic encephalopathy.

Marta Llansola1, Carmina Montoliu2, Ana Agusti1, Vicente Hernandez-Rabaza1, Andrea Cabrera-Pastor1, Belen Gomez-Gimenez1, Michele Malaguarnera1, Sherry Dadsetan1, Majedeline Belghiti1, Raquel Garcia-Garcia1, Tiziano Balzano1, Lucas Taoro1, Vicente Felipo3.   

Abstract

The cognitive and motor alterations in hepatic encephalopathy (HE) are the final result of altered neurotransmission and communication between neurons in neuronal networks and circuits. Different neurotransmitter systems cooperate to modulate cognitive and motor function, with a main role for glutamatergic and GABAergic neurotransmission in different brain areas and neuronal circuits. There is an interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in HE. This interplay may occur: (a) in different brain areas involved in specific neuronal circuits; (b) in the same brain area through cross-modulation of glutamatergic and GABAergic neurotransmission. We will summarize some examples of the (1) interplay between glutamatergic and GABAergic neurotransmission alterations in different areas in the basal ganglia-thalamus-cortex circuit in the motor alterations in minimal hepatic encephalopathy (MHE); (2) interplay between glutamatergic and GABAergic neurotransmission alterations in cerebellum in the impairment of cognitive function in MHE through altered function of the glutamate-nitric oxide-cGMP pathway. We will also comment the therapeutic implications of the above studies and the utility of modulators of glutamate and GABA receptors to restore cognitive and motor function in rats with hyperammonemia and hepatic encephalopathy.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive function; GABAergic neurotransmission; Glutamatergic neurotransmission; Hepatic encephalopathy; Hyperammonemia; Minimal hepatic encephalopathy

Mesh:

Substances:

Year:  2014        PMID: 25447766     DOI: 10.1016/j.neuint.2014.10.011

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  15 in total

Review 1.  Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease.

Authors:  Rafael Ochoa-Sanchez; Christopher F Rose
Journal:  J Clin Exp Hepatol       Date:  2018-08-18

2.  Endozepine-4 levels are increased in hepatic coma.

Authors:  Giulia Malaguarnera; Marco Vacante; Filippo Drago; Gaetano Bertino; Massimo Motta; Maria Giordano; Michele Malaguarnera
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

3.  Lactulose decreases neuronal activation and attenuates motor behavioral deficits in hyperammonemic rats.

Authors:  Natália Ferreira Mendes; Flora França Nogueira Mariotti; José Simões de Andrade; Milena de Barros Viana; Isabel Cristina Céspedes; Márcia Regina Nagaoka; Luciana Le Sueur-Maluf
Journal:  Metab Brain Dis       Date:  2017-09-05       Impact factor: 3.584

4.  Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes.

Authors:  Georg Oeltzschner; Markus Butz; Thomas J Baumgarten; Nienke Hoogenboom; Hans-Jörg Wittsack; Alfons Schnitzler
Journal:  Metab Brain Dis       Date:  2015-09-11       Impact factor: 3.584

5.  Covert hepatic encephalopathy: elevated total glutathione and absence of brain water content changes.

Authors:  Georg Oeltzschner; Markus Butz; Frithjof Wickrath; Hans-Jörg Wittsack; Alfons Schnitzler
Journal:  Metab Brain Dis       Date:  2015-11-12       Impact factor: 3.584

6.  Role of serine protease inhibitor, ulinastatin, in rat model of hepatic encephalopathy: aquaporin 4 molecular targeting and therapeutic implication.

Authors:  Rehab E Abo El Gheit; Marwa Mohamed Atef; Ghada A Badawi; Walaa M Elwan; H A Alshenawy; Marwa Nagy Emam
Journal:  J Physiol Biochem       Date:  2020-08-14       Impact factor: 4.158

7.  Hyperammonemia Enhances GABAergic Neurotransmission in Hippocampus: Underlying Mechanisms and Modulation by Extracellular cGMP.

Authors:  María Sancho-Alonso; Raquel Garcia-Garcia; Vicent Teruel-Martí; Marta Llansola; Vicente Felipo
Journal:  Mol Neurobiol       Date:  2022-03-23       Impact factor: 5.590

8.  Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.

Authors:  Giulia Malaguarnera; Gaetano Bertino; Giuseppe Chisari; Massimo Motta; Michele Vecchio; Marco Vacante; Filippo Caraci; Carmela Greco; Filippo Drago; Giuseppe Nunnari; Michele Malaguarnera
Journal:  BMC Psychiatry       Date:  2016-11-15       Impact factor: 3.630

9.  Ammonium chloride alters neuronal excitability and synaptic vesicle release.

Authors:  Roman M Lazarenko; Claire E DelBove; Claire E Strothman; Qi Zhang
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

Review 10.  Recent advances in hepatic encephalopathy.

Authors:  Victoria Liere; Gurkarminder Sandhu; Sharon DeMorrow
Journal:  F1000Res       Date:  2017-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.